After a 36-share conversion, Medpace (MEDP) director Carley holds 27,861 common shares.
Medpace Holdings, Inc. director Brian T. Carley converted 36 restricted stock units into 36 common shares on September 30, 2026. Following this transaction, Carley directly holds 27,861 common shares and 35 restricted stock units. The original grant on November 28, 2025, consisted of 143 restricted stock units vesting in four equal installments.
After converting stock units into 28 shares, Medpace (MEDP) director McCarthy holds 12,303 shares directly.
Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III converted 28 restricted stock units into 28 shares of common stock on September 30, 2026. Following this transaction, his direct holdings in common stock amounted to 12,303 shares. The restricted stock units were part of a grant issued in November 2025, vesting in approximately equal installments through 2026.
After a 32-share grant conversion, Medpace (MEDP) director Kraft holds 987 shares directly.
Medpace Holdings, Inc. (MEDP) director Robert O. Kraft converted 32 restricted stock units into 32 common shares on September 30, 2026. Following this transaction, he directly holds 987 common shares. This conversion was part of a 130-unit award granted in November 2025, with units vesting in installments throughout 2026.
Medpace Holdings CEO August Troendle sells $30.3m in stock
Medpace Holdings CEO August Troendle sold 48,667 shares of common stock in two transactions on September 29 and 30, 2026, totaling approximately $30.3 million. Following these sales, he directly holds 338,225 shares and indirectly owns 4,733,019 shares through Medpace Investors, LLC. This insider trading news follows Medpace's strong Q2 2026 results and updated guidance, which led to varied analyst ratings and increased price targets.
Medpace Holdings President & CEO Trades $30.32M In Company Stock
Medpace Holdings President & CEO, August J Troendle, sold 48,667 shares of the company stock for a total of $30,320,929, according to an SEC filing on October 1. The company, a contract research organization, reported a 17.24% revenue growth rate as of June 30, 2026, and has a P/E ratio of 35.13. Medpace Holdings shares were up 0.58% at $599.51 as of Friday morning.
Medpace Holdings CEO August Troendle sells $30.3m in stock By Investing.com
Medpace Holdings CEO August J. Troendle sold 48,667 shares of common stock in two transactions on September 29 and September 30, 2026, totaling approximately $30.3 million. Following these sales, he directly holds 338,225 shares and indirectly owns over 4.7 million shares. This news follows Medpace's strong Q2 2026 results, which surpassed expectations and led to raised guidance, prompting varied analyst ratings and price targets.
Form 4 Medpace Holdings Inc For: 2 October By Investing.com
This article from Investing.com is a standard financial report titled "Form 4 Medpace Holdings Inc For: 2 October." It indicates a filing related to Medpace Holdings Inc. (MEDP) but provides no further details on the content of the Form 4. The main body of the article appears to be boilerplate content from Investing.com, including general financial market data and popular news headlines, rather than specific information about the Medpace filing.
With EPS Growth And More, Medpace Holdings (NASDAQ:MEDP) Makes An Interesting Case
Medpace Holdings has demonstrated a strong ability to grow earnings per share (EPS) by 23% per year over the last five years, indicating efficient capital utilization. While the EPS growth is impressive, the company's P/E ratio of 29.1x suggests that the market has high expectations for its future performance. Investors should consider the sustainability of its growth and other financial metrics before making investment decisions.
Medpace Holdings, Inc. (MEDP) Stock forecasts
This article provides a daily report from Vickers highlighting the top five companies with the largest insider purchase transactions and the top five with the largest insider sales transactions based on dollar value. The report, published on October 1, 2026, covers companies across financial services, basic materials, real estate, healthcare, and consumer defensive sectors. It also promotes premium screener tools for more detailed insights.
Medpace Holdings Insider Sold Shares Worth $30,320,929, According to a Recent SEC Filing
An insider at Medpace Holdings has sold shares totaling $30,320,929, as reported in a recent SEC filing. This transaction is part of a series of insider share sales from the company, with previous sales ranging from hundreds of thousands to millions of dollars. Medpace Holdings is a global clinical contract research organization specializing in Phase I-IV clinical development services for the biotechnology, pharmaceutical, and medical device industries.
Enterprise value to EBIT forward of Medpace Holdings, Inc. – HAN:01P
This page from TradingView provides financial information for Medpace Holdings, Inc. (01P) on the Hannover Stock Exchange, specifically focusing on its enterprise value to EBIT forward. The content indicates that the market was closed with no trades at the time of viewing.
Two days of CEO share sales at Medpace (MEDP) were executed through an open-window limit order.
Medpace Holdings, Inc. President & CEO August J. Troendle sold a total of 48,667 common shares over two days. The sales, totaling approximately $30.32 million, occurred on September 29 and September 30, 2026, via limit orders placed during an open window period, with no Rule 10b5-1 plan reported. Troendle maintains indirect beneficial ownership of over 4.7 million shares through Medpace Investors, LLC.
Here's How Much $100 Invested In Medpace Holdings 10 Years Ago Would Be Worth Today
Medpace Holdings (NASDAQ: MEDP) has significantly outperformed the market over the last decade, with an average annual return of 35.51%. An investment of $100 in MEDP stock ten years ago would now be worth $2,048.90, highlighting the power of compounded returns. The company currently holds a market capitalization of $17.42 billion.
Insider Decision: August J Troendle Offloads $1.59M Worth Of Medpace Holdings Stock
August J Troendle, President & CEO of Medpace Holdings (NASDAQ: MEDP), recently sold 2,564 shares of the company's stock for a total of $1,589,941. Medpace Holdings, a late-stage contract research organization, shows positive revenue trends and strong EPS but exhibits below-average profitability with a low gross margin. The company's valuation metrics, including P/E, P/S, and EV/EBITDA ratios, suggest potential undervaluation compared to industry averages.
Long term debt to total assets ratio of Medpace Holdings, Inc. – HAN:01P
This article provides financial data for Medpace Holdings, Inc. (HAN:01P), specifically its long-term debt to total assets ratio. The data is presented under the "Financials" section of the company's profile on TradingView, indicating a focus on core financial metrics. The specific value and change percentage for the ratio are mentioned.
UBS Initiates Coverage of Medpace (MEDP) with Neutral Rating and $673 Price Target
UBS has initiated coverage of Medpace (MEDP) with a Neutral rating and a $673 price target, noting a positive outlook for the CRO sector but cautioning on Medpace's high valuation and booking variability. GuruFocus indicates MEDP is modestly overvalued by 15.8% compared to its intrinsic value, despite a strong GF Score of 97/100 reflecting robust fundamentals and growth. Insider selling totaling $436.7 million over the past year further contributes to the cautious sentiment.
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History
This Yahoo Finance article provides a detailed overview of Medpace Holdings, Inc. (MEDP), including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's role as a clinical research organization offering drug and medical device development services globally. The article also presents performance comparisons against the S&P 500 and recent earnings trends.
Medpace Holdings Insider Sold Shares Worth $1,589,941, According to a Recent SEC Filing
An insider at Medpace Holdings recently sold shares totaling $1,589,941. This transaction was disclosed in a recent SEC filing, indicating a significant sale by a company insider. Further details would typically be available in the full SEC document.
Medpace Holdings, Inc. (MEDP) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding Medpace Holdings, Inc. (MEDP), showcasing its stock performance and various analyst opinions. It highlights MEDP's recent market outperformance and upcoming financial results announcement, while also featuring comparisons with other stocks and discussions on its valuation.
At about $620 a share, Medpace (MEDP) CEO sells stock on two dates: 2,410 shares and 154 shares
Medpace Holdings, Inc. CEO August J. Troendle sold a total of 2,564 common shares in late September 2026. The sales included 2,410 shares on September 28, 2026, at a weighted average price of $620.07, and 154 shares on September 25, 2026, at $620.60, generating a total of approximately $1.59 million. Troendle also indirectly holds over 4.7 million shares through Medpace Investors, LLC, which he solely controls.
Medpace Holdings CEO August J. Troendle sells $6.75m in stock By Investing.com
Medpace Holdings CEO August J. Troendle sold 10,880 shares of company stock for approximately $6.75 million on September 17, 2026. The sale occurred after Medpace shares surged 37% over six months, with the stock currently appearing overvalued. Following the transaction, Troendle retains significant direct and indirect holdings in the company.
Medpace Holdings CEO August J. Troendle sells $6.75m in stock
Medpace Holdings CEO August J. Troendle sold 10,880 shares of the company's stock for $6,749,952 on September 17, 2026. This transaction occurred after Medpace shares had surged 37% over six months, with the company’s market capitalization reaching $17.27 billion. Despite the sale, Troendle retains significant direct and indirect ownership in the company.
Medpace Holdings CEO August Troendle sells $44.4m stock
Medpace Holdings CEO August Troendle sold approximately $44.4 million worth of company stock in late September 2026, across two transactions. Despite these insider sales, the company has seen aggressive share buybacks and positive analyst revisions, following strong Q2 2026 results that surpassed Wall Street expectations. While the stock has surged, InvestingPro analysis suggests it may be overvalued at current levels.
Form 4 Medpace Holdings Inc For: 27 September By Investing.com
This article from Investing.com announces the filing of Form 4 for Medpace Holdings Inc. on September 27. It briefly mentions the stock symbol MEDP and includes a general market overview with various financial data. The content is primarily a placeholder for the Form 4 announcement.
Form 4 Medpace Holdings Inc For: 26 September By Investing.com
This article from Investing.com announces the filing of Form 4 for Medpace Holdings Inc. on September 26. It includes stock performance data and various financial market indices.
Medpace CEO August Troendle sells $27.4m in company stock
Medpace CEO August J. Troendle sold approximately $27.4 million worth of company stock through two transactions on September 23 and September 24, 2026. These sales, executed via a limit order, involved 16,083 shares at an average of $628.64 and 27,833 shares at an average of $621.33. Following these transactions, Mr. Troendle retains significant direct and indirect holdings in Medpace, while the stock has seen a 33% surge over six months, despite an InvestingPro analysis suggesting overvaluation.
CEO sells shares on two days at Medpace (MEDP); a separate entry lists 4,733,019 indirectly held shares.
Medpace Holdings, Inc.'s President & CEO, August J. Troendle, reported direct sales of 16,083 shares at $628.64 on September 23, 2026, and 27,833 shares at $621.33 on September 24, 2026. These transactions were executed via limit orders during an open window period, with no Rule 10b5-1 plan in place. Additionally, an indirect holding of 4,733,019 shares by Medpace Investors, LLC, over which Troendle has sole voting and investment control, was noted.
Have Insiders Sold Medpace Holdings Shares Recently?
Medpace Holdings' CEO, President & Chairman, August Troendle, recently sold US$44 million worth of stock, reducing his holding by 1.4%. This follows a larger sale of US$62 million earlier in the year at a slightly lower price. While there have been no insider purchases, the company is showing earnings growth, and insiders still retain 19% ownership.
Insider Transaction: August J Troendle Sells $44.43M Worth Of Medpace Holdings Shares
August J Troendle, President & CEO of Medpace Holdings, sold 70,901 shares of the company worth $44.43 million, as reported in a recent SEC filing. The article also provides a company overview, financial performance metrics, and insights into the significance of insider activity for investment decisions. Medpace Holdings currently trades at $619.0 per share, showing a 0.89% increase during Thursday's morning session.
Medpace (MEDP) CEO sold 49,018 shares on Sept. 22 at a $628.11 average price.
Medpace Holdings, Inc. (MEDP) President & CEO, August J. Troendle, sold a total of 70,901 common shares over two days in September 2026. He sold 21,883 shares on September 21, 2026, at a weighted average price of $623.29 per share, and an additional 49,018 shares on September 22, 2026, at a weighted average price of $628.11 per share. These sales were executed through limit orders during an open window period and no Rule 10b5-1 plan was reported.
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will report its third-quarter 2026 financial results after market close on October 21, 2026. The company will host a conference call on October 22, 2026, at 9:00 a.m. ET to discuss these results. Interested parties must register in advance for the call, and a webcast replay along with a supplemental slide presentation will be available on Medpace's investor relations website.
MEDP FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
Rosen Law Firm is encouraging investors of Medpace Holdings, Inc. (NASDAQ: MEDP) to secure legal counsel before the June 8, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates and growth expectations between April 22, 2025, and February 9, 2026. Investors who purchased Medpace common stock during this period may be entitled to compensation.
MEDP DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
The Rosen Law Firm is reminding investors of Medpace Holdings, Inc. (NASDAQ: MEDP) who incurred losses exceeding $100,000 to secure legal counsel before the June 8, 2026, lead plaintiff deadline. This alert pertains to a securities class action lawsuit filed on behalf of purchasers of Medpace common stock between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates and growth expectations.
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will report its third quarter 2026 financial results after market close on Wednesday, October 21, 2026. The company will host a conference call on Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. Interested parties can register via a provided link or access a webcast on Medpace's investor relations website.
Medpace Holdings President & CEO Trades $6.75M In Company Stock
Medpace Holdings (NASDAQ: MEDP) President & CEO, August J Troendle, sold 10,880 shares of company stock for a total of $6,749,952 on September 21, 2026. This insider transaction was revealed in an SEC Form 4 filing. The article also provides a company overview, financial metrics including revenue growth, profitability, debt management, and market valuation.
Medpace Holdings Insider Sold Shares Worth $6,749,952, According to a Recent SEC Filing
An insider at Medpace Holdings sold shares valued at $6,749,952, as reported in a recent SEC filing. The transaction involved Dr. August J. Troendle, who disposed of 18,368 shares at an average price of $367.49 per share. This sale has reduced Dr. Troendle's direct ownership in the company to 2,933,707 shares.
Medpace (NASDAQ: MEDP) CEO sells shares, holds 504,273 directly
Medpace Holdings, Inc. CEO, August J. Troendle, sold 10,880 shares of common stock on September 17, 2026, at a weighted average price of $620.40 per share. Following this transaction, Troendle directly holds 504,273 shares and indirectly controls 4,733,019 shares through Medpace Investors, LLC. The sale was executed via a limit order during an open window period, and the reported price ranged from $620.00 to $622.21 per share.
Medpace Holdings Insider Sold Shares Worth $6,749,952, According to a Recent SEC Filing
An insider at Medpace Holdings has sold shares totaling $6,749,952, as disclosed in a recent SEC filing. The article, which requires a membership to view full details, is part of a series of news items concerning insider transactions at Medpace Holdings. Medpace Holdings, Inc. is a global clinical contract research organization providing comprehensive clinical development services.
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will release its third quarter 2026 financial results after market close on Wednesday, October 21, 2026. The company will host a conference call on Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. Interested parties can register for the call and access the webcast and supplemental presentation on the "Investors" section of Medpace's website.
Medpace Holdings, Inc. - Common Stock (Nasdaq:MEDP) Price Chart
This article provides the current stock price and basic market data for Medpace Holdings, Inc. (Nasdaq: MEDP). As of September 23, 2026, at 4:00 PM EDT, MEDP was trading at $617.15, down 2.07% or $13.04. The page also offers various financial tools and links to detailed company information.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Medpace Holdings, Inc. (MEDP) on behalf of investors who purchased securities prior to April 22, 2025. The investigation aims to determine if Medpace or its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist in the investigation.
Jefferies reiterates Medpace stock rating at Hold with $560 target
Jefferies has reiterated a Hold rating for Medpace Holdings Inc. (NASDAQ:MEDP) with a $560 price target. The current stock price of $587.52 suggests it is overvalued according to InvestingPro data. The firm noted improving demand for Medpace's services and efficiency gains due to a more experienced workforce, though they anticipate AI benefits will largely accrue to sponsors rather than contract research organizations.
Jefferies reiterates Medpace stock rating at Hold with $560 target By Investing.com
Jefferies has reiterated a Hold rating on Medpace Holdings Inc. (NASDAQ: MEDP) with a price target of $560.00, noting that the stock is currently trading above this target and appears overvalued based on InvestingPro data. The firm's analysis, following a headquarters visit, highlighted improving demand, strong revenue growth, and productivity gains for Medpace, partly offset by reduced backlog visibility due to increasing interim analyses and potential moderation of gains if growth accelerates. Despite AI's potential to improve efficiency, Jefferies expects most economic benefits to accrue to sponsors rather than Medpace.
Jefferies reiterates Medpace stock rating at Hold with $560 target By Investing.com
Jefferies maintained its Hold rating on Medpace Holdings Inc. (NASDAQ:MEDP) with a $560 price target, despite the stock currently trading above this target. The firm's assessment, following a headquarters visit, highlighted improving demand, strong revenue growth, productivity gains, and potential AI efficiency benefits for sponsors rather than contract research organizations. This comes after Medpace reported strong Q2 2026 results, leading other firms like BMO Capital and TD Cowen to adjust their price targets.
Medpace Holdings Insider Sold Shares Worth $403,176, According to a Recent SEC Filing
A recent SEC filing reveals that an insider at Medpace Holdings sold shares valued at $403,176. This sale is part of a series of insider transactions at the company, with several other significant sales reported in August. The article also provides a company profile for Medpace Holdings, outlining its services as a clinical contract research organization.
Medpace Holdings CEO August J. Troendle Sells 650 Shares at $620.27 Each in August 2026
Medpace Holdings CEO August J. Troendle sold 650 shares of the company's common stock on August 27, 2026, at a weighted average price of $620.27 per share. Following this transaction, Troendle directly holds 539,894 shares and indirectly owns 4,733,019 shares through Medpace Investors, LLC. The sale was executed via a limit order during an open trading window.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged corporate wrongdoing. The firm encourages Medpace investors who purchased securities before April 22, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning investors incur no out-of-pocket costs unless the firm is successful in recovering funds.
Medpace (NASDAQ: MEDP) insider sells 15,978 shares in August trades
Medpace Holdings, Inc. (NASDAQ: MEDP) President & CEO, August J. Troendle, sold a total of 15,978 shares of common stock in August 2026. These sales occurred on August 21 and August 24 at weighted average prices of $624.45 and $620.23 respectively, totaling approximately $9.97 million. Troendle also indirectly holds over 4.7 million shares through Medpace Investors, LLC.
Medpace Holdings Insider Sold Shares Worth $2,125,816, According to a Recent SEC Filing
An insider at Medpace Holdings sold shares valued at $2,125,816, as reported in a recent SEC filing. This transaction follows other significant insider sales for the company in August. Medpace Holdings, a global clinical contract research organization, provides comprehensive clinical development services to the biotechnology, pharmaceutical, and medical device industries.
MEDP - Why Medpace Outperforms Competitors in the Mid-Sized Biotech Niche
Medpace Holdings (MEDP) is a clinical research organization (CRO) that specializes in serving small and mid-sized biopharma companies, handling the complex process of clinical trials from design to regulatory approval. The company's strength lies in its comprehensive expertise, global infrastructure, and integrated trial management system, which provides a competitive edge despite contract cancellability. While Medpace demonstrates strong financial quality with high margins and low capital expenditure, its current share price reflects a demanding valuation, indicating investors are already pricing in significant future growth.
